Aberdeen Group plc Acquires 429,351 Shares of Novo Nordisk A/S $NVO

Aberdeen Group plc grew its stake in Novo Nordisk A/S (NYSE:NVO) by 231.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 614,866 shares of the company’s stock after purchasing an additional 429,351 shares during the quarter. Aberdeen Group plc’s holdings in Novo Nordisk A/S were worth $31,284,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. True Wealth Design LLC lifted its stake in Novo Nordisk A/S by 209.8% in the third quarter. True Wealth Design LLC now owns 443 shares of the company’s stock valued at $25,000 after buying an additional 300 shares during the period. Guerra Advisors Inc acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $25,000. Strengthening Families & Communities LLC acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth about $30,000. Allianz SE increased its stake in shares of Novo Nordisk A/S by 70.0% in the 3rd quarter. Allianz SE now owns 578 shares of the company’s stock valued at $32,000 after acquiring an additional 238 shares during the last quarter. Finally, Financial Life Planners bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $33,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently weighed in on NVO. Kepler Capital Markets lowered shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Wolfe Research began coverage on shares of Novo Nordisk A/S in a research note on Thursday, March 26th. They issued a “peer perform” rating for the company. Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Finally, Citigroup assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 27th. They issued a “neutral” rating for the company. Four equities research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $65.56.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo launched a multi‑month subscription program for Wegovy to lower out‑of‑pocket cost and improve adherence, which could bolster retail uptake and stabilize revenue from self‑pay patients. Slash Your Wegovy Costs: Novo Nordisk Reveals First-Ever Subscription Plan
• Positive Sentiment: Company cites cross‑trial data (ORION) showing oral Wegovy produced greater mean weight loss and fewer discontinuations vs. Lilly’s new pill — a claim that, if borne out commercially, helps defend market share in the oral GLP‑1 segment. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Wegovy was cleared by a UK drug‑pricing body for heart‑disease prevention, expanding the eligible patient pool by ~1.2M people — a potential medium‑term sales tailwind in the U.K. Novo’s Wegovy cleared by UK drug price watchdog for heart disease, expanding access by 1.2 million people
• Positive Sentiment: Pipeline progress — including once‑a‑week insulin work and early triple‑agonist studies — supports longer‑term growth optionality beyond current GLP‑1 competition. What Does Novo Nordisk’s (NVO) Once A Week Insulin Mean For Investors?
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — a sign analysts see recovery potential but not an immediate buy catalyst. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market commentary notes shares have at times held up despite new competition, suggesting investors believe some threats are already priced in. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: Eli Lilly’s oral GLP‑1 (Foundayo) gained FDA approval and is launching, creating a fierce new competitor in the oral obesity market and pressuring expectations for Novo’s market share and pricing. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Low‑cost generic semaglutide in India forced Novo to cut Wegovy/Ozempic prices by as much as 48% in that market, highlighting pricing vulnerability where generics emerge. Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
• Negative Sentiment: Policy risk: U.S. proposals to impose heavy tariffs on branded drugs could raise costs or complicate pricing strategies for multinational drugmakers. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Valuation and sentiment questions after a ~43% Y/Y drop: investors are re‑pricing Novo on the view that competitive erosion, price competition and upcoming patent expiries will constrain near‑term growth. Is Novo Nordisk (NYSE:NVO) Pricing Fair After A 43% One Year Share Price Decline?

Novo Nordisk A/S Price Performance

Shares of NVO opened at $36.92 on Friday. The stock has a 50 day simple moving average of $43.43 and a 200 day simple moving average of $49.79. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $81.44. The company has a debt-to-equity ratio of 0.61, a quick ratio of 0.57 and a current ratio of 0.80. The firm has a market capitalization of $164.86 billion, a PE ratio of 10.64, a P/E/G ratio of 8.75 and a beta of 0.73.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. Sell-side analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The business also recently disclosed a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be given a $1.2751 dividend. This represents a yield of 723.0%. The ex-dividend date of this dividend is Monday, March 30th. Novo Nordisk A/S’s payout ratio is currently 50.43%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.